Analysis of the mechanism of action and efficacy of tilsiparatide/tilpotide

Tirzepatide is a novel dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) receptor agonist. Its unique mechanism of action gives it significant advantages in the control of type 2 diabetes and weight management. Unlike traditional GLP-1 receptor agonists, tisiparatide simultaneously activates GIP and GLP-1 receptors, synergistically enhances insulin secretion and inhibits glucagon release, thereby effectively reducing fasting and postprandial blood glucose levels. This dual mechanism can also improve pancreatic beta cell function, delay gastric emptying, and increase satiety, thereby contributing to weight control.

In clinical studies, tisiparatide can not only significantly reduce glycated hemoglobin (HbA1c), and its blood sugar reduction is better than that of many traditional antidiabetic drugs. It can also achieve weight loss of up to 20% in multiple trials, becoming the world's first drug with dual approved indications for hypoglycemic and weight loss. In addition, tilsiparatide may also improve cardiometabolic indicators, such as lowering blood pressure and improving lipid metabolism, so it is considered to have potential in the treatment of metabolic syndrome.

Tisiparatide has been approved in many countries such as the United States and the European Union for the treatment of type 2 diabetes and obesity. Its weekly subcutaneous injection method improves patient compliance and makes long-term management possible. Although tilsiparatide has not yet been widely marketed in China, it has broad prospects for use worldwide and is expected to enter the Chinese market in the future, providing new treatment options for patients with diabetes and obesity.

In general, tilsiparatide has multiple targets and significant efficacy, opening up a new situation for comprehensive intervention in metabolic diseases.

Reference materials:https://www.drugs.com/tirzepatide.html